NUI Galway’s Prof Matt Griffin presents NEPHSTROM to an array of international audiences

Professor Matthew Griffin of the National University of Ireland in Galway delivered lectures presenting NEPHSTROM research at a range of international venues in recent months. Below, find the titles of his talks, with the date, and audience composition.

  • “Diabetic Kidney Disease: The Promise of Regenerative Therapies”. REMEDI Seminar. Biomedical Sciences, NUI Galway

Date: May 23rd 2019.

Audience type: regenerative medicine researchers and postgraduate students

Number of attendees: 30

  • “Modulating the course of diabetic kidney disease: Are the pieces coming together?” Nephrology Grand Rounds, Mayo Clinic, Rochester, MN, USA.

Date: October 1st 2019.

Audience type: clinical nephrologists, nephrology trainees, laboratory scientists, translational researchers

Number of attendees: 60

  • “Modulating the Course of Diabetic Kidney Disease: The Role of Allogeneic Mesenchymal Stromal Cell Therapies” Seminar, Dept. of Immunology, Hebei Medical University, Shijiazhuang, China,

Date: October 31st 2019.

Audience type: laboratory researchers, postgraduate students, clinicians

Number of attendees: 50

  • “Understanding and targeting abnormal inflammation in chronic kidney disease”. HBB Seminar, NUI Galway,

Date: February 12th 2020.

Audience type: laboratory researchers, postgraduate students

Number of attendees: 30

  • “Stem cell research and chronic kidney disease in diabetes”. Advances in Diabetes Seminar. Hilton Hotel Kilmainham, Dublin

Date: March 6th 2020.

Audience type: consultant endocrinologists and endocrinology trainees

Number of attendees: 15

NEPHSTROM presented at RenalToolBox ITN Workshop, Galway

Coordinator Prof Tim O’Brien from NUI Galway presented aspects of NEPHSTROM at a recent Marie Curie Innovative Training Network workshop hosted in Galway. Coordinator O’Brien’s talk was entitled, “MSCs as a Therapy for Diabetic Complications.“ The online workshop was held on October 13th and 14th.

RenalToolBox, the ITN hosting the workshop, is taking a coordinated approach to develop novel tools and technologies to assess the safety and efficacy of cell-based regenerative medicine therapies with a focus on kidney disease. See the workshop programme here.

Regenerative Medicine Network publishes EU-MSC2 meeting report featuring NEPHSTROM

NEPHSTROM results were presented at EU-MSC2,  a bi-annual event, organized by partners Leiden University Medical Center in The Netherlands. The meeting assembles researchers, clinicians and cell product developers working within EU-sponsored research consortia, that focus on mesenchymal stromal cell (MSC) therapy for immune-related disorders and tissue regeneration. EU-MSC2, a much-anticipated event provides excellent opportunities for networking, […]

NEPHSTROM Publication in PLoS One journal

Congratulations to NEPHSTROM partners at the Centre for Public Health, Queen’s University Belfast, the University Hospitals Birmingham, and the National University of Ireland Galway for their recent review: The impact of chronic kidney disease on developed countries from a health economics perspective: A systematic scoping review published in PLoS ONE.

Sarah Elshahat, Paul Cockwell, Alexander P. Maxwell, Matthew Griffin, Timothy O’Brien, and Ciaran O’Neill are the authors of the study which appears in the March 24, 2020 edition of the open-access journal; PLoS ONE 15(3): e0230512. https://doi.org/10.1371/journal.pone.0230512

 

NEPHSTROM study published in Scientific Reports

Congratulations to the team of researchers Tomás Patrick Griffin, Md Nahidul Islam, Deirdre Wall, John Ferguson, Damian Gerard Griffin, Matthew Dallas Griffin and Paula M. O’Shea who published a NEPHSTROM-acknowledged study in Scientific Reports.  The open-access paper titled “Plasma dephosphorylated-uncarboxylated Matrix Gla-Protein (dp-ucMGP): reference intervals in Caucasian adults and diabetic kidney disease biomarker potential” can be found in the 5th of December 2019 edition with doi  https://doi.org/10.1038/s41598-019-54762-2. Alternatively, download the pdf here.

“Recent studies suggest a possible association between dephosphorylated-uncarboxylated MGP (dp-ucMGP) and glomerular filtration rate (GFR). This study aimed to establish normative data in an adult Caucasian population and to explore the potential utility of dp-ucMGP in patients with diabetes mellitus (DM) with and without diabetic kidney disease (DKD).”

NEPHSTROM presented at the RESTORE Horizon meeting, Berlin

Our Coordinator Prof Tim O’Brien of NUI Galway presented REDDSTAR and NEPHSTROM at the RESTORE Horizon (https://www.restore-horizon.eu/): 1st Advanced Therapies Science meeting in Berlin, Germany held on November 25th and 26th, 2019.

New NEPHSTROM publication from NUI Galway team

“Human mesenchymal stromal cells broadly modulate high glucose-induced inflammatory responses of renal proximal tubular cell monolayers” authored by Md Nahidul Islam, Tomás P. Griffin, Elizabeth Sander, Stephanie Rocks, Junaid Qazi, Joana Cabral, Jasmin McCaul, Tara McMorrow and Matthew D. Griffin at NUI Galway was published today, the 19th of November 2019. The open-access paper appears in Stem Cell Research & Therapy (2019) 10:329, DOI: 10.1186/s13287-019-1424-5 You can download the pdf here.

Abstract:

Background

Renal proximal tubular epithelial cells (RPTEC) are dysfunctional in diabetic kidney disease (DKD). Mesenchymal stromal cells (MSC) may modulate DKD pathogenesis through anti-inflammatory mediators. This study aimed to investigate the pro-inflammatory effect of extended exposure to high glucose (HG) concentration on stable RPTEC monolayers and the influence of MSC on this response.

Methods

Morphologically stable human RPTEC/TERT1 cell monolayers were exposed to 5 mM and 30 mM (HG) D-glucose or to 5 mM D-glucose + 25 mM D-mannitol (MAN) for 5 days with sequential immunoassays of supernatants and end-point transcriptomic analysis by RNA sequencing. Under the same conditions, MSC-conditioned media (MSC-CM) or MSC-containing transwells were added for days 4–5. Effects of CM from HG- and MAN-exposed RPTEC/MSC co-cultures on cytokine secretion by monocyte-derived macrophages were determined.

Results

After 72–80 h, HG resulted in increased RPTEC/TERT1 release of interleukin (IL)-6, IL-8, monocyte chemoattractant protein (MCP)-1 and neutrophil gelatinase-associated lipocalin (NGAL). The HG pro-inflammatory effect was attenuated by concentrated (10×) MSC-CM and, to a greater extent, by MSC transwell co-culture. Bioinformatics analysis of RNA sequencing data confirmed a predominant effect of HG on inflammation-related mediators and biological processes/KEGG pathways in RPTEC/TERT1 stable monolayers as well as the non-contact-dependent anti-inflammatory effect of MSC. Finally, CM from HG-exposed RPTEC/MSC transwell co-cultures was associated with attenuated secretion of inflammatory mediators by macrophages compared to CM from HG-stimulated RPTEC alone.

Conclusions

Stable RPTEC monolayers demonstrate delayed pro-inflammatory response to HG that is attenuated by close proximity to human MSC. In DKD, this MSC effect has the potential to modulate hyperglycemia-associated RPTEC/macrophage cross-talk.

NEPHSTROM PI Prof. Matt Griffin visits leading US medical centre Mayo Clinic to discuss EU-funded mesenchymal stromal cell projects

Prof. Matt Griffin of the National University of Ireland Galway visited the Division of Nephrology and Hypertension and the William J von Liebig Transplant Center at Mayo Clinic, Rochester, Minnesota between September 27th and October 2nd, 2019. While there, he engaged with clinical investigators involved in a range of Mayo Clinic research initiatives in regenerative medicine and transplantation. He gave seminars entitled “Modulating the course of diabetic kidney disease: Are the pieces coming together?” and “Allogeneic MSC in Corneal Re-transplantation: From Pre-clinical Evidence to Regulatory Approval” which focussed on the progress of the NUI Galway-coordinated NEPHSTROM and VISICORT (www.visicort.eu) consortia respectively.

Commenting on the visit, Prof. Griffin, who trained and was a faculty member at Mayo Clinic between 1992 and 2008 said: “There are many shared interests and collaborative links between leading academic centres in the US such as Mayo Clinic and European Commission-funded consortia such as NEPHSTROM and VISICORT. Looking ahead to the next EU research and innovation programme, Horizon Europe, I believe that there will be exciting opportunities to further strengthen these links in the areas of regenerative medicine and cellular therapies for the long-term benefit of people with reduced quality of life due to chronic health conditions.”

International Clinical Trials Day 2019 at the CRF Galway

The HRB Clinical Research Facility Galway in Ireland hosted a public event to celebrate International Clinical Trials Day on May 20th 2019. Exhibition stands were on display and informational meetings were held throughout the day to inform the public of all areas of clinical research being undertaken at the facility.

A particular stand was dedicated to the CRF Galway’s stem cell work to inform the public of the cell therapy projects being undertaken with partners within the National University of Ireland Galway and with European partners.  NEPHSTROM was showcased here, as were the related projects VISICORT and ADIPOA-2.

Dr Veronica McInerney comments, “Great interest was expressed in this evolving therapeutic area with approximately 100 members of the public stopping by to hear about what cell therapy involves and to learn about the projects from the clinical researchers on the day.”

Dr Veronica McInerney, CRF Galway

Clinical researchers and visitors, CRF Galway